Innate Pharma S.A.

Ladies and gentlemen, thank you for joining us and welcome to the Nate Farmer First Quarter 2026 Business Update and Financial Results. After today's remarks, we will host a question and answer session. If you'd like to ask a question, please press Start 1 on your telephone keypad to raise your hand. I will now hand the conference over to Stephanie Kornan, Vice President of Investor Relations, Communication and Commercial Strategy at Nate Farmer. Please go ahead.

Good morning and good afternoon, everyone. Thank you for joining us for EnateParma's Q1 2026 Business Update and Financial Results Conference Call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. To briefly cover today's agenda, our CEO, Jonathan Dickinson, will begin with a strategic overview and outlook. Sonia Quarantino, our chief medical officer, and Yanis Morel, our chief operating officer and I, will then provide updates on Lactamab, IPH4502, and next-generation ADCs, as well as AstraZeneca partner program, including Monalizumab and IPH5201. Jonathan will then return with closing remarks. Frederic Lombard, our CFO, will join us for the Q&A. With that, I will now hand it over to Jonathan.

Thank you, Stephanie. Good morning to those joining from the US and good afternoon to our European participants. Turning to slide five. We continue to execute against our strategy, which is focused on our three priority assets, with discipline, and we're pleased with the strong progress we are seeing today. Starting with lakutamab, our anti-CUR3DL2 monoclonal antibody, which is being developed in cutaneous T cell lymphoma, or CTCL. As you remember, we received the FDA clearance to proceed with the TELEMAC III phase III trial for lacutumab in CTCL, and we expect to be able to initiate the study in the second half of 2026. We have made progress in negotiating non-dilutive financing options for lacutumab, including potential pharma partnerships and royalty-based structures. From a commercial perspective, We believe that lacutamab represents a meaningful opportunity in CTCL in both the United States and Europe, with additional life cycle expansion opportunities in peripheral T cell lymphoma. Moving to IPH4502, our differentiated Nectin-4 ADC, which is being evaluated in advanced solid tumors, The phase one study is ongoing and approaching completion of enrollment in the dose escalation phase and backfill cohorts. As highlighted on the slide, we continue to observe preliminary antitumor activity in heavily pretreated patients, including in urophilic cancer patients previously treated with EV. We believe that IPH4502 may represent a differentiated opportunity, both in the post-PADSF urophilic cancer setting and potentially across a broader range of solid tumors. And finally, turning to monolizumab, our AstraZeneca-partnered anti-NKG2A monoclonal antibody, which is being developed in non-small cell lung cancer. the ongoing Pacific Nine phase three study remains on track for a planned readout in the second half of 2026. From a financial perspective, the partnership also continues to represent a potentially important source of future value for Enate, including potential milestones, profit sharing in Europe, and royalties in the United States and the rest of the world. Overall, we believe these three assets provide Innate with a focused portfolio of differentiated clinical stage opportunities spanning both proprietary and partnered programs. I'll now hand over to Sonia and Stephanie for a more detailed review of the LACUTAMAB program.